Skip to content

A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)

Pancreatic Ductal Adenocarcinoma | Colorectal Cancer | Biliary Tract Cancer

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with chemotherapy can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn:

* About the safety and how well people tolerate sacituzumab tirumotecan alone or with chemotherapy
* How many people have the cancer respond (get smaller or go away) to treatment

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has one of the following cancers:

* Unresectable or metastatic colorectal cancer
* Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC)
* Advanced and/or unresectable biliary tract cancer (BTC)
* Has received prior therapy for the cancer
* Has recovered from any side effects due to previous cancer treatment

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* History of severe eye disease
* Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention
* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

Study Location

The Ottawa Hospital Cancer Centre ( Site 0027)
The Ottawa Hospital Cancer Centre ( Site 0027)
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Study Coordinator

613-737-7700 x70185
Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0022)
Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0022)
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Study Coordinator

5148908000
Study Sponsored By
Merck Sharp & Dohme LLC
Participants Required
More Information
Study ID: NCT06428409